Papzimeos is the first and only FDA-approved therapy for the treatment of adults with RRP.
Introduction: PAPZIMEOS™ is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with recurrent respiratory papillomatosis.
Dosage: 5×10¹¹ particle units (PU) per injection, given SC 4 times over 12 weeks.
Usage: Prior to first dose, surgical debulking of visible papillomas is recommended to minimize residual disease. Supplied as a single-dose vial containing 5×10¹¹ PU in 1 mL suspension.
Contraindications: None.
Warnings & Precautions: Injection-site reactions Monitor patients for at least 30 minutes after Rx. Thrombotic events.
Adverse reactions: Most common (≥5%): injection-site reactions, fatigue, chills, fever, muscle pain, and nausea.